Vascular endothelial growth factor C (
VEGF-C) is a critical activator of
tumor lymphangiogenesis that recently has been strongly implicated in the
tumor metastasis process. In this study, we identified that
HRG-beta 1 stimulated up-regulation of
VEGF-C mRNA and
protein of human
breast cancer cells in a dosage- and time-dependent manner and that this up-regulation was de novo
RNA synthesis-dependent. The
HRG-beta 1-induced increase in
VEGF-C expression was effectively reduced by treatment with
Herceptin, an antibody specifically against HER2. Also, when HER2 was overexpressed in MCF-7 cells that resulted in an evident increase in the
VEGF-C level, suggesting an essential role of HER2 in mediating
VEGF-C up-regulation by
HRG-beta 1.
NF-kappa B has been shown to be probably involved in
interleukin-1 beta- or
tumor necrosis factor-alpha-induced
VEGF-C mRNA expression in human fibroblasts. Here we found that
HRG-beta 1 could stimulate
NF-kappa B nuclear translocation and
DNA-binding activity via the
I kappa B alpha phosphorylation-degradation mechanism. Blockage of the
NF-kappa B activation cascade caused a complete inhibition of the
HRG-beta 1-induced elevation of
VEGF-C. In promoter-reporter assay, the
luciferase activities of the reporter constructs, including the putative
NF-kappa B site deleted and mutated form were significantly reduced after
HRG-beta 1 treatment as compared with the 1.5-kb
VEGF-C promoter. Although investigating the upstream
kinase pathway(s) involved in
HRG-beta 1-elicited
NF-kappa B activation and
VEGF-C up-regulation, we found that HRG-beta1 could activate extracellular signal-regulated
protein kinase 1/2,
phosphatidylinositol 3'-kinase, and
p38 mitogen-activated protein kinase (MAPK) in MCF-7. However, only
SB203580 (a specific inhibitor of
p38 MAPK), not
PD98059 nor
LY294002, blocked the up-regulation of
VEGF-C by
HRG-beta 1. A similar inhibition in
VEGF-C expression was obtained by cell transfection with dominant-negative p38 (p38AF). Interestingly, the
HRG-beta 1-induced
NF-kappa B activation cascade was also effectively blocked by
SB203580 treatment or p38AF transfection. Our data thus suggests that
HRG-beta 1 stimulated a
NF-kappa B-dependent up-regulation of
VEGF-C through the
p38 MAPK signaling pathway in human
breast cancer cells.